Proponents of psychedelic drugs advocate for their approval in treating conditions like depression and PTSD. The US health secretary, Robert F Kennedy Jr, supports this initiative, surprising many with a proposed timeline for approval. However, concerns arise about the potential rush to market and the association with Kennedy's controversial views. The FDA is reconsidering MDMA for PTSD treatment, with new initiatives to expedite drug approvals. While some experts express optimism, others caution against bypassing rigorous clinical trials, emphasizing the need for scientific validation.